MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset
MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ocular hypertension. SIGHT-2 is designed to assess dose optimization for the company’s lead asset, LL-BMT1, a drug-eluting contact lens to treat glaucoma, and is preceded by the completion of the company’s SIGHT-1 study that validated the MediPrint process and contact lenses for treating human subjects.
The concluded SIGHT-1 trial successfully achieved its objectives by showing a favorable safety and tolerability profile and demonstrated a sustained efficacy signal from a single dose. Consequently, MediPrint is proceeding with this previously announced SIGHT-2 study for LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. Patient enrollment is slated to begin imminently.
“I’m excited we’re starting our SIGHT-2 clinical study because this is a key milestone in MediPrint’s plan to provide a necessary ocular treatment option for millions of contact lens wearing patients,” Praful Doshi, Founder, Chairman, and Interim CEO, said in a company news release. “Eye care professionals and glaucoma patients alike are eagerly seeking an alternative to administering ophthalmic drops daily and our weekly medicated contact lens will fulfill that need. We expect to finalize our LL-BMT1 dose by the first half of 2023 as we continue progressing on our path toward FDA submission.”
MediPrint has retained CBCC Global Research to facilitate the regulatory, clinical operations, data management and biometric services for the SIGHT-2 study. “CBCC is thankful to the MediPrint management and board members for their confidence in both our team and ability to execute,” stated Manoj Vyas, CEO for CBCC Global Research.
The company also announces a move into its new San Diego headquarters. The larger facility will house corporate offices along with research and development functions and an ISO compliant GMP manufacturing facility. The new building and larger space will facilitate MediPrint scaling its current and future pipeline and is equipped to allow for developing both clinical and commercial stage product.